OrliLab publishes educational information about orlistat, OTC Alli 60 mg, prescription Xenical 120 mg, generics and selected weight-management medication alternatives. This policy explains how we approach evidence, U.S. regulatory records, medical accuracy, product comparisons, pharmacy information, commercial independence and editorial corrections. The aim is careful, understandable coverage—not treatment recommendations or promises of pharmacy supply.
Last updated: October 14, 2026
A reliable medication page needs evidence suited to the exact claim. Approved indications require product-specific labeling; side effects require safety and clinical evidence; pharmacy licensing requires official registration checks; and current prices or stock require information from the actual seller. One source cannot establish all of these facts.
The policy guides how we distinguish evidence from speculation and keep medical claims separate from purchasing information. Learn more about the site in About OrliLab.
Our standards center on factual accuracy, clear definitions, careful sourcing, explicit limits, editorial independence and a useful page-specific focus. We aim to explain what the evidence establishes, what remains uncertain and when the reader needs a clinician, pharmacist, insurer or regulator rather than an article.
Claims about expected weight reduction are not a license to promise personal results. Brand approval, ingredient identity, treatment indication, dosage form and U.S. pharmacy availability are separate matters.
| Principle | How OrliLab applies it |
|---|---|
| Accuracy | Match claims to the correct drug, strength, formulation, studied population and jurisdiction. |
| Neutrality | Explain tradeoffs without presenting any medicine as universally best. |
| Source relevance | Prefer official labels, regulatory records and appropriately designed medical research. |
| Topic boundaries | Keep ingredient, brand, safety, commercial access and pricing intents distinct. |
| Transparency | Qualify dated claims, unknown stock and limitations of evidence. |
| Accountability | Provide a way to report errors and review supported corrections. |
For approved indications, precautions, dosage forms and reported adverse events, we prioritize current FDA prescribing information, Drug Facts for OTC products, and product labeling available through DailyMed. For approval and generic-equivalence questions, FDA Orange Book and Drugs@FDA records are relevant. FDA safety communications can establish major new warning changes.
For medical interpretation and comparative studies, we consider clinical guidelines, systematic reviews and original trials suited to the question. Advertising copy, user reviews, an affiliate listing or a manufacturer’s promotional headline are not adequate substitutes for primary evidence.
We evaluate whether the material supports the specific medicine, formulation and patient group under discussion. An FDA-authorized product can have a label different from another product with the same ingredient; safety findings from one trial need their stated limitations.
An NDC listing may help identify a labeler or package but is not automatically proof of approval. Likewise, approval status does not establish whether a pharmacy has the medicine today.
| Claim | Preferred evidence | Additional context |
|---|---|---|
| U.S. labeled indications and contraindications | FDA labeling and DailyMed | Relevant clinical guidance |
| OTC status and Drug Facts warnings | FDA OTC records and actual Drug Facts | FDA Drug Safety Communications |
| Approved generics and equivalence | FDA Orange Book and Drugs@FDA | Product-specific approval and label records |
| NDC, labeler and package identity | FDA NDC Directory and DailyMed | Actual package and dispensing records |
| Weight-related efficacy | Randomized trials and reviews | Approved product label, population and trial methods |
| Pharmacy safety | FDA BeSafeRx and state boards of pharmacy | Documented dispenser identity |
| Insurance and fees | Current plan and provider documents | Product-specific pharmacy quotation |
Alli 60 mg and Xenical 120 mg both contain orlistat but have different U.S. regulatory categories and product instructions. Alli is a nonprescription drug with adult-use conditions in its Drug Facts; prescription-strength products require lawful authorization and dispensing.
We avoid suggesting that taking multiple OTC capsules creates an appropriate substitute for a prescribed 120 mg regimen, or that a general orlistat statement automatically applies to both products. The differences are explained in orlistat OTC status and 120 mg versus 60 mg.
Medication warnings change. We aim to reflect material official updates promptly and identify their dates where appropriate. For example, the FDA’s June 10, 2026 communication strengthened OTC Alli warnings about rare kidney injury and stones and advised particular action for specified symptoms.
The source establishes a labeling update; it does not mean every orlistat user will develop kidney injury. We distinguish common effects from serious warning signs in side effects and kidney risk articles.
Treatment trials vary in eligibility, dose, background lifestyle programs, diabetes status, duration, outcomes, missing data and discontinuation. We identify the studied product and population when reporting clinical findings and avoid applying trial averages as a personal forecast.
When a direct randomized comparison is absent, we do not describe unrelated placebo-controlled trials as head-to-head proof. We also distinguish weight outcomes observed during diabetes treatment from a medicine’s actual FDA-approved obesity indication. See orlistat efficacy for ingredient-specific evidence.
Orlistat comparisons involve brands, generics, strengths and access conditions. Other weight-management drugs may use the same active ingredient across brands with differing approvals. Wegovy and Ozempic contain semaglutide but are not the same approved product; Mounjaro and Zepbound contain tirzepatide under distinct labels.
Oral GLP-1 tablets are not interchangeable simply because they are swallowed. We describe their product-specific administration and indication context. A new product or presentation is not evidence that a different product may be used in its place.
We differentiate a product’s application holder, manufacturer, labeler, distributor and pharmacy. These roles can belong to different businesses. An approved generic may be marketed under a different labeler, and an authorized generic has a distinct regulatory pathway from a conventional abbreviated new drug application.
We avoid converting a product code, historical approval or inactive listing into a claim of present availability, brand continuity or automatic therapeutic interchangeability. See orlistat generics.
OrliLab is primarily written for U.S. readers. Foreign product catalogs, overseas labeling and international pharmacy offers cannot establish that a given medicine or strength has the same approval, access rules or supply chain in the United States.
We describe foreign information as such when relevant and do not treat imported packaging, unusually low prices or non-U.S. prescribing claims as evidence of a lawful U.S. sale.
An online pharmacy should comply with applicable licensing and valid-prescription requirements. We use the FDA’s BeSafeRx resources and relevant state licensing information to explain independent checks.
We do not publish invented rankings of dispensers, promise prescription approval after a telehealth visit or imply that a retailer listing verifies stock. The online safety and online pharmacy guides explain that boundary.
Pricing, insurance benefits, coupons, pharmacy contracts and delivery fees change. OrliLab focuses on stable factors: correct product, strength, quantity, cash versus adjudicated insurance payment, legitimate dispenser and full final charge.
We do not claim a permanent national lowest price, guaranteed discount, active coupon or plan-specific coverage without suitable verification. See orlistat prices and insurance.
OrliLab may receive affiliate compensation when readers follow commercial links. The presence of a commercial relationship should not change what we say about clinical evidence, prescribing requirements, comparative safety or product identity.
Sponsored or affiliate links should be disclosed where used, and they should not be presented as proof that a product, pharmacy or clinician is suitable. We make no promise of approval, delivery, authenticity or current stock on behalf of third parties.
We avoid fabricated healthcare credentials, fictitious medical review, unsupported superiority claims, exaggerated clinical certainty, made-up pricing, undisclosed conflicts and invented pharmacy inventory. We do not offer individualized dosage selection or instructions to bypass prescription safeguards.
We also avoid recommending that users stop prescribed diabetes, antiseizure or weight-management medicines based only on an article. Medical changes belong to the treating professional.
Editorial checking is not the same as professional clinical review. Our Medical Review Process explains the additional scrutiny appropriate for indications, warnings and interactions; the Medical Reviewer page explains verification of credentials and attribution.
We only describe a page as reviewed by a named clinician when such review has actually occurred and can be documented. We do not manufacture names, qualifications, review dates or institutional affiliations.
When an authoritative source changes, we may update affected material and adjust qualifications, links or examples. Important safety information can warrant special attention. Routine editorial improvements may concern readability and the specificity of claims.
Please submit supported corrections via Contact, ideally with the precise URL, passage and authoritative source. We evaluate suggestions but cannot promise a response schedule or publication of every submitted view.
OrliLab is not a pharmacy, clinician, telehealth platform or emergency service. Our articles are general educational content, not a prescription, diagnosis, clinical relationship, individualized regimen or guarantee that a treatment is suitable.
Consult appropriately qualified professionals about personal health questions. The Terms of Use and Privacy Policy provide additional website information.